Skip to main content

Vivos Therapeutics, Inc.

VVOS
Exchange
Nasdaq
Industry
Surgical & Medical Instruments & Apparatus
SEC CIK
0001716166

No open-market purchases or sales by Vivos Therapeutics, Inc. insiders were filed in the last 90 days; 22 institutions reported holding it in 13F filings for Q2 2026, worth $242.7K in total; no superinvestor holds it.

Q3 2024 vs. Q2 2024

How the institutions holding Vivos Therapeutics, Inc. changed between Q2 2024 and Q3 2024.

All holders in Q3 2024All holders in Q2 2024

13F holders of VVOS: Q2 2024 compared with Q3 2024
MeasureQ2 2024Q3 2024Change
Holders1923+4
Shares186.9K245.1K+58.1K (+31.1%)
Value$433.8K$630.7K+$196.9K (+45.4%)

New holders (6)

Institutions that held Vivos Therapeutics, Inc. at the end of Q3 2024 but not at the end of Q2 2024.

Institutions new to VVOS in Q3 2024
InstitutionSharesValue% of portfolio
Omers Administration Corp25,000$65.3K0.00%
Sabby Management, LLC20,502$53.5K0.74%
Two Sigma Investments, LP20,482$53.5K0.00%
Millennium Management LLC12,001$31.3K0.00%
UBS Group AG78$2040.00%
Voisard Asset Management Group, Inc.1$30.00%

Sold out (2)

Institutions that held Vivos Therapeutics, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.

Institutions that sold out of VVOS in Q3 2024
InstitutionShares, Q2 2024Value, Q2 2024
Triad Wealth Partners, LLC2,818$6.26K
Newbridge Financial Services Group, Inc.1,275$2.83K